Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

NCT00896480 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00896480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00896480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2009
Completion date
November 3, 2014
Enrollment
24 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma